2440 related articles for article (PubMed ID: 18565894)
1. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.
Yao JC; Hassan M; Phan A; Dagohoy C; Leary C; Mares JE; Abdalla EK; Fleming JB; Vauthey JN; Rashid A; Evans DB
J Clin Oncol; 2008 Jun; 26(18):3063-72. PubMed ID: 18565894
[TBL] [Abstract][Full Text] [Related]
2. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
[TBL] [Abstract][Full Text] [Related]
3. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
[TBL] [Abstract][Full Text] [Related]
4. Increasing incidence of duodenal neuroendocrine tumors: Incidental discovery of indolent disease?
Fitzgerald TL; Dennis SO; Kachare SD; Vohra NA; Zervos EE
Surgery; 2015 Aug; 158(2):466-71. PubMed ID: 26013986
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine tumor epidemiology: contrasting Norway and North America.
Hauso O; Gustafsson BI; Kidd M; Waldum HL; Drozdov I; Chan AK; Modlin IM
Cancer; 2008 Nov; 113(10):2655-64. PubMed ID: 18853416
[TBL] [Abstract][Full Text] [Related]
6. Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006.
Navalkele P; O'Dorisio MS; O'Dorisio TM; Zamba GK; Lynch CF
Pediatr Blood Cancer; 2011 Jan; 56(1):50-7. PubMed ID: 21108439
[TBL] [Abstract][Full Text] [Related]
7. Incidence and survival patterns of rare anal canal neoplasms using the surveillance epidemiology and end results registry.
Metildi C; McLemore EC; Tran T; Chang D; Cosman B; Ramamoorthy SL; Saltzstein SL; Sadler GR
Am Surg; 2013 Oct; 79(10):1068-74. PubMed ID: 24160801
[TBL] [Abstract][Full Text] [Related]
8. Malignant neuroendocrine tumors: incidence and outcomes in pediatric patients.
Allan B; Davis J; Perez E; Lew J; Sola J
Eur J Pediatr Surg; 2013 Oct; 23(5):394-9. PubMed ID: 23444065
[TBL] [Abstract][Full Text] [Related]
9. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States.
Lee MR; Harris C; Baeg KJ; Aronson A; Wisnivesky JP; Kim MK
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2212-2217.e1. PubMed ID: 30580091
[TBL] [Abstract][Full Text] [Related]
10. Best prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single-center study.
Özaslan E; Bayram F; Karaca H; Gürsoy Ş; Öztürk F; Sözüer E; Abdurrezzak Ü; Yurci A; Can Sezgin G; Yıldırım A; Başpınar O; Kula M; Özkan M
Turk J Gastroenterol; 2016 Nov; 27(6):509-514. PubMed ID: 27852541
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of and prognostic factors for appendiceal carcinomas: a retrospective, population-based study.
Mo S; Zhou Z; Ying Z; Dai W; Xiang W; Han L; Li Q; Wang R; Cai G
Int J Colorectal Dis; 2019 Nov; 34(11):1915-1924. PubMed ID: 31642969
[TBL] [Abstract][Full Text] [Related]
12. Rare tumors of the colon and rectum: a national review.
Kang H; O'Connell JB; Leonardi MJ; Maggard MA; McGory ML; Ko CY
Int J Colorectal Dis; 2007 Feb; 22(2):183-9. PubMed ID: 16845516
[TBL] [Abstract][Full Text] [Related]
13. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971.
Ellis L; Shale MJ; Coleman MP
Am J Gastroenterol; 2010 Dec; 105(12):2563-9. PubMed ID: 20823835
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database.
Punekar SR; Kaakour D; Masri-Lavine L; Hajdu C; Newman E; Becker DJ
Am J Clin Oncol; 2020 Dec; 43(12):846-849. PubMed ID: 32910023
[TBL] [Abstract][Full Text] [Related]
15. The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study.
Tsai HJ; Wu CC; Tsai CR; Lin SF; Chen LT; Chang JS
PLoS One; 2013; 8(4):e62487. PubMed ID: 23614051
[TBL] [Abstract][Full Text] [Related]
16. The epidemiology of gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Chan A; Svejda B; Kidd M; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):1-18, vii. PubMed ID: 21349409
[TBL] [Abstract][Full Text] [Related]
17. Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years.
Sackstein PE; O'Neil DS; Neugut AI; Chabot J; Fojo T
Semin Oncol; 2018 Aug; 45(4):249-258. PubMed ID: 30348533
[TBL] [Abstract][Full Text] [Related]
18. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?
McCarthy DM
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963924
[TBL] [Abstract][Full Text] [Related]
19. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
Kuo EJ; Salem RR
Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245
[TBL] [Abstract][Full Text] [Related]
20. Gastric Neuroendocrine Tumors (G-Nets): Incidence, Prognosis and Recent Trend Toward Improved Survival.
Yang Z; Wang W; Lu J; Pan G; Pan Z; Chen Q; Liu W; Zhao Y
Cell Physiol Biochem; 2018; 45(1):389-396. PubMed ID: 29402806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
